Research ExplorerPublicationsDiscordant prostate specific antigen test results despite WH...

Discordant prostate specific antigen test results despite WHO assay standardization

Standard

Discordant prostate specific antigen test results despite WHO assay standardization. / Boegemann, Martin; Arsov, Christian; Hadaschik, Boris; Herkommer, Kathleen; Imkamp, Florian; Nofer, Jerzy-Roch; Gerß, Joachim; Albers, Peter; Semjonow, Axel.

In: INT J BIOL MARKER, Vol. 33, No. 3, 08.2018, p. 275-282.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Boegemann, M, Arsov, C, Hadaschik, B, Herkommer, K, Imkamp, F, Nofer, J-R, Gerß, J, Albers, P & Semjonow, A 2018, 'Discordant prostate specific antigen test results despite WHO assay standardization', INT J BIOL MARKER, vol. 33, no. 3, pp. 275-282. https://doi.org/10.1177/1724600818754750

APA

Boegemann, M., Arsov, C., Hadaschik, B., Herkommer, K., Imkamp, F., Nofer, J-R., Gerß, J., Albers, P., & Semjonow, A. (2018). Discordant prostate specific antigen test results despite WHO assay standardization. INT J BIOL MARKER, 33(3), 275-282. https://doi.org/10.1177/1724600818754750

Vancouver

Boegemann M, Arsov C, Hadaschik B, Herkommer K, Imkamp F, Nofer J-R et al. Discordant prostate specific antigen test results despite WHO assay standardization. INT J BIOL MARKER. 2018 Aug;33(3):275-282. https://doi.org/10.1177/1724600818754750

Bibtex

@article{8549d6e55bb54eb788db9bed2acaa16f,
title = "Discordant prostate specific antigen test results despite WHO assay standardization",
abstract = "INTRODUCTION: Total PSA (tPSA) and free PSA (fPSA) are the most commonly used biomarkers for early detection of prostate cancer. Despite standardization efforts, many available PSA assays may still produce discordant results. In the present study, we compared four PSA assays calibrated to the WHO standards 96/670 and 96/668 for tPSA and fPSA, respectively.METHODS: Within the scope of the Prostate Cancer Early Detection Study Based on a ''Baseline'' PSA Value in Young Men (PROBASE), we tested tPSA and fPSA in serum samples from 50 patients in the four different PROBASE sites using four WHO-calibrated assays from Roche (Elecsys, Cobas), Beckman-Coulter (Access-II) and Siemens (ADVIA Centaur). The comparison was performed using the Passing-Bablok regression method.RESULTS: Compared to Access, the median tPSA levels for Centaur, Elecsys, and Cobas were +3%, +11%-20%, and +17%-23%, respectively, while for median fPSA levels the differences for Centaur, Elecsys, and Cobas were +49%, +29%-31%, and +22%, respectively.DISCUSSION: Despite all investigated assays being WHO-calibrated, the Elecsys and Cobas tPSA assays produced considerably higher results than the Access and Centaur assays. Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 μg/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 μg/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.",
keywords = "Adult, Aged, Aged, 80 and over, Biomarkers, Tumor/blood, Biopsy, Early Detection of Cancer, Humans, Male, Middle Aged, Prostate-Specific Antigen/blood, Prostatic Neoplasms/blood, Reference Standards, World Health Organization",
author = "Martin Boegemann and Christian Arsov and Boris Hadaschik and Kathleen Herkommer and Florian Imkamp and Jerzy-Roch Nofer and Joachim Ger{\ss} and Peter Albers and Axel Semjonow",
year = "2018",
month = aug,
doi = "10.1177/1724600818754750",
language = "English",
volume = "33",
pages = "275--282",
journal = "INT J BIOL MARKER",
issn = "0393-6155",
publisher = "Wichtig Publishing",
number = "3",

}

RIS

TY - JOUR

T1 - Discordant prostate specific antigen test results despite WHO assay standardization

AU - Boegemann, Martin

AU - Arsov, Christian

AU - Hadaschik, Boris

AU - Herkommer, Kathleen

AU - Imkamp, Florian

AU - Nofer, Jerzy-Roch

AU - Gerß, Joachim

AU - Albers, Peter

AU - Semjonow, Axel

PY - 2018/8

Y1 - 2018/8

N2 - INTRODUCTION: Total PSA (tPSA) and free PSA (fPSA) are the most commonly used biomarkers for early detection of prostate cancer. Despite standardization efforts, many available PSA assays may still produce discordant results. In the present study, we compared four PSA assays calibrated to the WHO standards 96/670 and 96/668 for tPSA and fPSA, respectively.METHODS: Within the scope of the Prostate Cancer Early Detection Study Based on a ''Baseline'' PSA Value in Young Men (PROBASE), we tested tPSA and fPSA in serum samples from 50 patients in the four different PROBASE sites using four WHO-calibrated assays from Roche (Elecsys, Cobas), Beckman-Coulter (Access-II) and Siemens (ADVIA Centaur). The comparison was performed using the Passing-Bablok regression method.RESULTS: Compared to Access, the median tPSA levels for Centaur, Elecsys, and Cobas were +3%, +11%-20%, and +17%-23%, respectively, while for median fPSA levels the differences for Centaur, Elecsys, and Cobas were +49%, +29%-31%, and +22%, respectively.DISCUSSION: Despite all investigated assays being WHO-calibrated, the Elecsys and Cobas tPSA assays produced considerably higher results than the Access and Centaur assays. Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 μg/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 μg/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.

AB - INTRODUCTION: Total PSA (tPSA) and free PSA (fPSA) are the most commonly used biomarkers for early detection of prostate cancer. Despite standardization efforts, many available PSA assays may still produce discordant results. In the present study, we compared four PSA assays calibrated to the WHO standards 96/670 and 96/668 for tPSA and fPSA, respectively.METHODS: Within the scope of the Prostate Cancer Early Detection Study Based on a ''Baseline'' PSA Value in Young Men (PROBASE), we tested tPSA and fPSA in serum samples from 50 patients in the four different PROBASE sites using four WHO-calibrated assays from Roche (Elecsys, Cobas), Beckman-Coulter (Access-II) and Siemens (ADVIA Centaur). The comparison was performed using the Passing-Bablok regression method.RESULTS: Compared to Access, the median tPSA levels for Centaur, Elecsys, and Cobas were +3%, +11%-20%, and +17%-23%, respectively, while for median fPSA levels the differences for Centaur, Elecsys, and Cobas were +49%, +29%-31%, and +22%, respectively.DISCUSSION: Despite all investigated assays being WHO-calibrated, the Elecsys and Cobas tPSA assays produced considerably higher results than the Access and Centaur assays. Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 μg/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 μg/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers, Tumor/blood

KW - Biopsy

KW - Early Detection of Cancer

KW - Humans

KW - Male

KW - Middle Aged

KW - Prostate-Specific Antigen/blood

KW - Prostatic Neoplasms/blood

KW - Reference Standards

KW - World Health Organization

U2 - 10.1177/1724600818754750

DO - 10.1177/1724600818754750

M3 - SCORING: Journal article

C2 - 29734838

VL - 33

SP - 275

EP - 282

JO - INT J BIOL MARKER

JF - INT J BIOL MARKER

SN - 0393-6155

IS - 3

ER -